论文部分内容阅读
目的探讨超小剂量地西他滨治疗中危-1型骨髓增生异常综合征的疗效及副反应。方法收集2016年1月至2017年1月中国医科大学附属盛京医院血液科10例中危-1型骨髓增生异常综合征患者的临床资料。所有患者接受皮下注射地西他滨10 mg/d,第1~3天,第8、15、22天。32 d为1个疗程。评估其疗效及副反应。结果 6例例存在MDS相关基因突变。1个疗程结束时4例获得了临床改善,其中1例部分缓解(PR),3例血液学改善(HI),6例疾病稳定(SD)。3例患者完成3个疗程治疗,疗效评估显示,2例获得了临床改善,1例(33.3%)完全缓解(CR),1例血液学改善,1例SD。出现骨髓抑制4例,白细胞减少1例,贫血1例,血小板减少3例;2例出现严重的血小板减少。结论超小剂量地西他滨治疗中危-1型骨髓增生异常综合征安全有效。
Objective To investigate the efficacy and side effects of ultra-low dose decitabine in the treatment of patients with moderate-risk myelodysplastic syndrome. Methods The clinical data of 10 patients with myelodysplastic syndrome-1 myelodysplastic syndrome from Department of Hematology, Shengjing Hospital, China Medical University from January 2016 to January 2017 were collected. All patients received subcutaneous injection of decitabine 10 mg / d, days 1 to 3, days 8, 15, and 22. 32 d for a course of treatment. Evaluate its efficacy and side effects. Results Six cases had MDS related gene mutation. Four patients achieved clinical improvement at the end of one course of treatment, with one partially relieved (PR), three hematological improvements (HI) and six stable disease (SD). Three patients completed three courses of treatment. Efficacy evaluations showed that two patients achieved clinical improvement, one (33.3%) had complete remission (CR), one had hematologic improvement and one had SD. 4 cases of bone marrow suppression, leukopenia in 1 case, anemia in 1 case, thrombocytopenia in 3 cases; 2 cases of severe thrombocytopenia. Conclusion Ultra-low-dose decitabine is safe and effective in the treatment of moderate-risk myelodysplastic syndrome.